Earnings Call Transcript - INMB Q1 2020

Operator, Operator

Greetings and welcome to INmune Bio’s First Quarter 2020 Earnings Call. At this time all lines have been placed on a listen only mode and the floor will open for questions and comments following the presentation. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. David Moss, Co-Founder and CFO of INmune Bio. David, the floor is yours.

David Moss, CFO

Thank you, Latania and good afternoon everybody. We thank you for joining us for the call for INmune Bio’s first quarter 2020 financial results call. With me on the call is RJ Tesi, CEO and also Co-Founder of INmune Bio who will provide a business update. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provision of the private securities litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filing with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements which speak only as of the date they're made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information, events or circumstances. Now, I'd like to turn the call over to RJ Tesi, CEO of INmune Bio. RJ?

RJ Tesi, CEO

Thank you, David and thank everyone for joining the call in these difficult times – difficult and interesting I think is the best way to describe them. I will arrange my remarks to highlight key takeaways for the first quarter, the year-to-date and provide updates from our two platforms. Then I will turn it back to David Moss to discuss our financial results and upcoming milestones before we open the lines for Q&A. We'll start with the DN-TNF Platform. We have four therapeutic programs in development. These include INB03 for cancer, LIVNate for NASH. We have a new program that we're calling Quellor for treatment of cytokine storm related to COVID-19, and XPro1595 for Alzheimer's disease. I'll remind you that these are all from the same platform. I'll start with our newest program, Quellor, targeting cytokine storm to treat the complications of COVID-19. We initiated this program after completing a strategic gas assessment, and we are planning clinical trials with the DN-TNF Platform for the treatment of the complications of this disease. Our decision is based on the four TNF related attributes of COVID-19 and the pathophysiology of the disease. The first is cytokine storm. This is, shall we say, a top-line problem with COVID-19 and blunting the effects of the cytokine storm makes sense. Soluble TNF is a major part of the cytokine storm, and neutralizing soluble TNF is what the DN-TNF Platform does. But soluble TNF plays two other very important roles that are not as obvious to many. The first is that for tissue destruction to occur, immune cells must move from inside the blood vessel to outside the blood vessel and into the tissue where they cause damage. Soluble TNF, when it activates endothelial cells, causes them to upregulate ICAM-1 and VCAM-1. These proteins are sort of like traffic cops that signal to activated immune cells that are living by in the bloodstream to stop and exit the blood vessel. That's called trafficking into the tissue, where they cause damage. A more obscure role of soluble TNF is that it contributes to the coagulopathy, which is the cause of many of the complications related to this disease. When soluble TNF activates endothelial cells and macrophages, they upregulate tissue factor; tissue factor actually starts the coagulation cascade that results in much of the pathology associated with pulmonary, renal, vascular, and probably neurologic disease in patients. This coagulopathy is reflected by elevated D-dimer, a biomarker of severe disease and present in almost every patient who’s admitted to the hospital. Working with clinicians and the regulatory authorities, we are moving rapidly to start a clinical trial that will attempt to prevent the catastrophic complications of COVID-19, including the need for mechanical ventilation. We hope to be enrolling patients by July ideally in a program supported by non-dilutive funding. XPro is being used – XPro1595 is being used to treat Alzheimer's disease—an apt metaphor for this program as steady as she goes. We're confident in our goal to have data for review in October, if not sooner. We are beginning to plan for the Phase 2 trial, but we admit the pandemic has forced us to be creative. Future programs must require fewer trips to the clinic without sacrificing the ability to collect critical data or the quality of that data. We have some ideas; we're working to implement them and we'll tell you more about these in the future. INB03, our cancer program, is being targeted to treat women with metastatic HER2+ breast cancer, especially those with CNS mets. Just a couple of weeks ago, we announced the publication of an invited review in frontiers of oncology, entitled Tumor Necrosis Factor: An Opportunity to Tackle Breast Cancer by Roxana Schillaci. She is the lead thought leader that has been working with us on the role of TNF in cancers, especially breast cancer. This publication is part of an evolving body of work by Dr. Schillaci and our team on the role of soluble TNF and resistance to immunotherapies including trastuzumab and tyrosine kinase inhibitors. Just three days ago, Sophi Bruni, a doctoral student in Dr. Roxana Schillaci Lab presented work at the New York Academy of Sciences Frontiers in Immunotherapy 2020 meeting. That work demonstrated that a combination of Lapatinib, a PKI inhibitor, and INB03 overcomes resistance to trastuzumab in HER2+ breast cancer models. This work informs the design of our planned Phase 2 trial in women with brain mets from HER2+ breast cancer. Lapatinib is a dual EGFR HER2 inhibitor. It's part of the PKI class. It's a good drug for a difficult disease that suffers from early resistance. We believe we have identified this resistance mechanism. We are targeting women with HER2+ brain mets because both drugs cross the blood-brain barrier. Most of these women will also be expressing MUC4, which makes them resistant to trastuzumab-based therapies. Finally, the combination decreases myeloid derived suppressor cells, key immunosuppressive cells in the tumor microenvironment and makes cold tumors hot in animal models, and we hope this sets up this combination to be part of triple therapy that will include immune checkpoint inhibitors. I would just as an aside, tomorrow, AACR will be releasing their abstracts. This work is also being presented at the AACR. Originally, that was supposed to be the first release of the data, but as with many programs COVID-19 has changed the calendar. Moving to LIVNate for NASH, giving patients new livers was a big part of my previous life as a transplant surgeon, but there's a surgical saying that says the sign of a good surgeon is the one who can avoid an operation. And that is the goal of this therapy, to avoid the need for liver transplants. We have identified a novel pathogenic mechanism to treat NASH. We believe that LIVNate seals the intestinal leak that is critical in driving inflammation in the liver. The leaky gut results in a very high inflammatory cytokine load in the portal vein, two logs greater than what you see in the blood. The portal vein feeds blood directly from the intestinal tract into the liver, and this highly inflamed blood has predictable effects on the liver, causing inflammation, decreased hepatocyte survival, which ends up with fibrosis and changes in liver histology. The protocol is written, sites are identified, but we are delaying the initiation of this trial for now. Starting new trials in the COVID-19 era is challenging. Starting trials in a disease that is life-threatening poses a bigger challenge, and as we ramp up the COVID-19 effort, we are managing our drug supply with our existing programs. We have enough drug available to complete the Alzheimer's program and the planned COVID-19 program, but to support our expanding clinical programs, we have signed an agreement with KBI Biopharma to produce additional drugs. This concludes my comments on the DN-TNF Platform and I’ll move to the NK Priming Platform. The NK Priming Platform, which we call INKmune, has two therapeutic programs in the queue. INKmune will be studied in solid tumors and hematologic malignancies, ovarian cancer and high-risk MDS respectively. In April, we announced that the USPTO had provided formal notice of the allowance of a patent application entitled 'In Vivo Priming of Natural Killer Cells.' This is the first of several that are coming for this platform. The patent relates to and I quote, 'the method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient's own natural killer cells within the body to induce an in vivo response, namely the priming of NK cells for enhancing the innate immune response, and the NK cell ability to recognize and kill cancer cells in the patient.' I'll remind you, we do not give new NK cells. We believe, and we have excellent data to support it, that the patient’s cancer NK cells are fine. They have all the tools they need to kill cancer cells, but they need targeting assistance. They need to be turned on and that's what INKmune does. The newly allowed patent is expected to issue in approximately 60 days and will expire in 2036. This is just as I said one of the many of the company's IP or patents that we are expanding our portfolio and we believe our patent portfolio is one of our finest assets. The Phase 1 clinical programs in INKmune are being run in the UK. The UK is suffering mightily from the COVID-19 pandemic, as are we. Both programs have been somewhat delayed by the fact that they aren't allowing clinical trials to move forward because of the pressures on the hospital. We are cautiously optimistic that we can meet our goal to treat a patient within the high-risk MDS program by the end of the year. Realistically, we do not expect to treat a patient in the INKmune ovarian cancer trial until the first half of 2021. So with that, I will turn it over to David who will talk about financial results and upcoming milestones.

David Moss, CFO

Thank you, RJ. I'll provide a brief overview of our financial results and upcoming milestones. Net loss attributable to common stockholders for the first quarter ended March 31, 2020, was 2.1 million compared to 1.9 million for the quarter ended March 31, 2019. Research and Development expenses totaled approximately 0.8 million for the first quarter ended March 31, 2020, compared with approximately 0.6 million for the quarter ended March 31, 2019. General and administrative expense was approximately 1.3 million in each of the quarters ended March 31, 2020 and March 31, 2019. At March 31, 2020, the company had cash and cash equivalents of approximately 5.9 million with no debt. As of May 13, 2020, the company had approximately 10.8 million shares outstanding. Now, I'd like to list our upcoming catalysts. To reiterate what we have detailed in our press release, some of the milestone timelines have been updated due to the ongoing COVID-19 pandemic as RJ just spoke about. First, we expect to report the results of the ongoing Phase 1 XPro1595 trial in Alzheimer’s disease expected to be completed in the second half of 2020 and have data in October, possibly sooner. Second, we expect to submit an IND for Quellor for the prevention of pulmonary complications of COVID-19 infection this month or very early next month. Moreover, we are working to enroll the first patient in a Phase 2 Quellor program as soon as possible. Third, we expect to enroll the first patient in the Phase 2 INB03 program targeting trastuzumab-resistant HER2+ breast cancer using INB03 as part of combination therapy in mid-2021. Fourth, we expect to enroll the first patient in Phase II LIVNate for NASH in mid-2021. Fifth, we expect to enroll the first patient in Phase I INKmune in high-risk MDS cancer in the second half of 2020. Sixth, we expect to enroll the first patient in the Phase 1 INKmune ovarian cancer program by mid-2021. So, as a small company, we have a lot of catalysts coming up. We remain very focused on meeting our milestones and delivering data and rewarding investors’ faith and patience in the development of our business. At this point, I'd like to thank you for your time and attention, and I'd like to turn it back to the operator for questions and answers. Latania, can you please poll for questions.

Operator, Operator

Thank you. Our first question comes from Jonathan Aschoff with ROTH Capital Partners. Please proceed with the question.

Jonathan Aschoff, Analyst

Thank you. Hi, guys. I have two questions. The first is, since Lapatinib is the drug with which you intend to combine DN-TNF with Phase II, can't it be argued that that drug has kind of already had its heyday and therefore maybe restoring Lapatinib sensitivity isn't as commercially exciting as restoring trastuzumab sensitivity? You want to discuss that a little?

RJ Tesi, CEO

Yeah, that's a great question, Jonathan. The problem is that once you get down to the way clinicians treat patients, once the patient has failed a drug, once they have relapsed, basically on trastuzumab, which is what happens when a patient develops metastatic disease, particularly brain metastases, they move on, right? It's a difficult discussion frequently to have with clinicians when they say, to say well, we can now – if you give Lapatinib, let’s say you give Lapatinib with trastuzumab, the patient's going to respond. They get nervous about that, but let's talk – let's really take the next step. Obviously, there are a number of these trastuzumab drug conjugates out there now, and some of them have shown a bit of a signal in the brain. The problem is with a trastuzumab-based conjugate, if the patient is expressing MUC4, which almost all of these metastatic patients do, in fact, trastuzumab can’t bind to HER2. So, actually, trastuzumab resistance is a, you know, shall we say a biomarker for resistance to any trastuzumab based strategy? So, I think, I actually think the future, and I'm speculating here, is that I admit Lapatinib maybe had its day in the sun, but it is indicated for the indication and there are other PKIs that show some signal in these indications. I just don't have data, but I predict in the future that we will be combining INB03 with a number of PKIs because this may be a class effect. I don't know that yet. It may be. We are doing that research, but we have indications that that might be the case. So, I accept your comment, but it's hard to go against tradition. The tradition is once a clinician – once a patient has progressed on a therapy, they move on.

Jonathan Aschoff, Analyst

Okay, what questions will be dear headed? Can you help us, David better understand the quarterly R&D expense trend over 2020, just looking at the drop from 4Q to the first quarter?

David Moss, CFO

I'm sorry, Jon, you want the R&D expense going forward?

Jonathan Aschoff, Analyst

Yes, yes, just because there was such a big drop from the fourth quarter of 2019 to the first quarter of 2020.

David Moss, CFO

I'll tell you what, we're currently evaluating the costs related to the COVID trial. The first part of the trial will be somewhere between 3 million to 5 million. We're looking at non-dilutive activity related to that. We're also looking at whether we can run what percentage of the trials we run in Australia, which allows us to get a rebate. I would like to take that offline with you, if you don't mind, Jonathan and have a call with you about that after this, if you don't mind.

Jonathan Aschoff, Analyst

No problem. That's all I have. Thank you.

Operator, Operator

Our next question comes from Jason McCarthy with Maxim. Please proceed with your question.

Jason McCarthy, Analyst

Hey, guys, thanks for taking the questions. Can you talk a little bit about the amount of drug product that you do have manufactured, you mentioned it earlier? And how much of that would be applicable to a COVID study and for that COVID study, you know, can you walk us through a little bit of what you're thinking in terms of a trial size and maybe stage of disease would it be severe/ICU intubated or something more mild-to-moderate or something in the middle, maybe in the hospital, but not in the ICU just yet, just a little bit more clarity there. And David, on the back end of that would be, can you just elaborate a little bit on your relationship with KBI Pharma, because they are a great manufacturing partner. They support coherence and a bunch of other names. This talk a little bit about drug manufacturing with KBI.

RJ Tesi, CEO

Yeah, so let me start. So, we have, you know, we have more than enough drug to complete the COVID trial and the Alzheimer’s trial, but we don't have enough drug to jump into another trial that may have extensions. When you set up a trial, for instance, with a cancer patient, if that patient is doing well on the therapy, the expectation is you carry them until the end of the trial. So, we cannot make open-end commitments. The COVID trial is interesting. When we talk to the FDA, we sent in one design and they pushed back. They actually suggested a better design. They are asking us to do a two-step Phase 2 trial that requires a 100 patient proof-of-concept that will ride into a fully powered pivotal trial that will allow us to really sit with the FDA and see what the next steps are. The way we’ve designed it, so the 100 patients is a randomized blinded trial, one-to-one randomization. The follow-on trial is 260 patients so a total of 360 patients will be treated one-to-one with that no-go decision after the first 100 patients. The target patient is one who is admitted to the hospital with hypoxia, a saturation level less than 94%, but not someone who's in the ICU. The purpose of the trial is to keep the patient out of the ICU and the primary endpoint, and once again, this was dictated by the FDA, is respiratory failure and we define respiratory failure as progression to mechanical ventilation, which includes any ventilatory support—CPAP, BiPAP and traditional intubation with mechanical ventilation. The primary endpoint is respiratory failure. Part of the reason behind this is, as you know, there has been a really rapid change about how people are using intubation; people are using non-endotracheal tube forms of ventilation as long as they can, but our goal is to take a patient who comes in, who may need oxygen support, and keep them from sliding down that slippery slope. We are very interested in the other pathologies with COVID-19. I mentioned the endothelial activation, which I think is underestimated in the disease. It is the cause of the coagulopathy, which contributes to renal disease and contributes to neurologic complications. It is likely a big part of the problems before they develop the more traditional form of ARDS. The patients we're treating will not have ARDS. It's not that we don't think the drug is good for patients with ARDS. It's just that that’s, in my opinion, a different patient population. I'd rather keep patients out of the ICU off mechanical ventilation than try to wrestle them once they've gone that far. So, I'll stop there, and let David answer the question and then let you respond, Jason.

David Moss, CFO

Jason, thanks for the question. Yeah, we signed an agreement with KBI. They're a wonderful group. We've had a lot of discussions with them and we have a very good consultant that we use as an intermediary to help us on the manufacturing front. We actually run this through our UK subsidiary, so it's eligible for a rebate from the UK government. It's broken into really two different phases, and the first phase is really to do a pilot scale manufacturing and then the second phase is to do the clinical grade material manufacturing. We estimate it's about a 14 to 18-month agreement, a long-term relationship because as this – if this goes well, obviously, we will need to continually manufacture the drug as the programs expand, but the first part of it.

Jason McCarthy, Analyst

Okay, great. And where would the trial be conducted? Would you be in Australia or someplace ex-U.S. where you get rebates? I thought I recall Australia was one of your sites?

RJ Tesi, CEO

Well, it was. I tell you, I was interested because as you know, we love the rebates right. It's been a great source of funding, but if you've been, you know, if you happen to look at their Australian government website, they have done an extraordinary job of squashing the curve. I think two days ago, they had around 80 patients in the hospital and 40 in the ICU, and that was for the whole country. So, this trial will primarily be run in the United States, and I will say one of the other areas we're very interested in, as you know, is that Black and Hispanics have a rough go of it with this disease. There’s a big debate about whether this is because of comorbidities or if there’s something else going on. So, I predict we will be running this in, you know, the centers or parts of the country where the disease tidal wave is starting to hit—places in the Mid South, Texas, the Southwest, and the Southeast. We plan to have a patient population that looks a lot like the demographics, you know, a third Caucasian, a third Hispanic and a third Black because when you're treating almost 400 patients, you can really learn a lot from them. But…

Jason McCarthy, Analyst

Is the fall season coming in Australia? Is that a possible factor for not having a few cases? Are you watching that? Or…

RJ Tesi, CEO

Oh, yeah, we're watching that, but I think the problem, there’s really a couple of issues there. One, what's happening there is they are about to start the influenza season. What’s going to happen is the same thing that’s going to happen here as they begin to open up; they're going to have spots of disease. They’re going to see more cases than they see now, but the question is, are they going to have the kind of intensity where you can pick three or four hospitals and pick up enough patients? It’s a moving target really, Jason. I am not ruling out having sites in Australia, but the trial will be driven for the most part out of the U.S.

Jason McCarthy, Analyst

Okay, perfect. Thanks for taking the question.

Operator, Operator

Our next question comes from Michael Erwin with Universe Securities. Please proceed with your question.

Michael Erwin, Analyst

Hi. I actually have a few questions. So, you said before that there was going to be some pushback of the trials for some of your plans. Are there any, you said before that you would release more data, but is there more information about the clinical design? Are there any plans of exceeding the results for those trials to make up for that one-year delay?

David Moss, CFO

Well, certainly the – no. Once we start the trial, the trial design is fixed. I mean, at the end of the day, as you know what the limiting factor to almost every trial is, speed of enrollment. So, at this point, you know, they are just being reset, to move back to reflect the pandemic.

Michael Erwin, Analyst

Okay, and then there's been news online about complications with COVID-19 showing in pediatrics of a Kawasaki-like disease. Are there any plans of looking into this because there are some small links between TNF inhibitors and treatment options for Kawasaki disease?

RJ Tesi, CEO

Actually, we are – thank you for that question. We're following that very closely. You are absolutely right. There is a big role of TNF in Kawasaki syndrome. We expect that there's a similar role in this multi-system inflammatory disease; I believe that's the name. We’ve not yet seen anyone publish cytokine data. We're looking for that very closely. We expect it's going to model what we see in Kawasaki disease. One of the things that the FDA made very clear in their response to us for a pre-IND and actually in the guidance they just released on Monday for clinical trials related to COVID-19 is that you need a pediatric plan. Although they don't hold you hostage to that plan, you have to have that plan very quickly. Right now, we view that disease as our potential pediatric plan. I emphasize potential; we've not discussed it with the FDA yet. We await to see some data to further support our interest, but once that our IND, assuming everything goes well, is open, and we start having follow-on discussions with the FDA, this is a disease that we think we have the perfect drug for because remember, it targets TNF. It targets endothelial cell activation, which is a big part of this disease and is not immunosuppressive. One of the major differentiators of our anti-inflammatory strategy for many others out there is that we do not cause immunosuppression. In fact, we improve the immune response. We have tested this drug in models of Eastern Equine Encephalitis and in Coxsackie B3 with the NIAID and we did not make those animals worse. They did not die faster. We didn't make them get better either, but they did not go worse. So, this drug is not immunosuppressive, which is an important consideration when you're treating people that have viral disease.

Michael Erwin, Analyst

Alright, that's everything I got. Thank you very much.

Operator, Operator

Our next question comes from Arthur He with H.C. Wainwright. Please proceed with your question.

Arthur He, Analyst

Good afternoon, RJ and David. Thanks for taking my question. It is Arthur for RK. Most of my question has been answered. I just have two maybe two quick ones. The first one for your COVID-19 program, if I recall correctly you expect to start the trial in July. Could you give us more color on your expectations for the overall timing of the program?

RJ Tesi, CEO

Yeah, so good question, you know. Obviously, the calculation of July is, you know, obviously depends on the FDA. The FDA has been spectacular in dealing with the COVID-19 issue. They are quick in their responses, and they’re clear. They are here to help, which is often not the way it seems when you're a small biotech because they can be a rough taskmaster. The rate of enrollment obviously would depend completely on where the disease is in the US. I think that anyone who thinks the disease is going to disappear in the summer, there are few people that do; I'm not one of those people. As I mentioned earlier, I think it's going to roll across the South and the South Central in the Midwest, and then in the fall we’re probably going to have secondary outbreaks where the first outbreaks are in the Northeast and the West Coast. I think it's going to be here for a while. The current plan is that we're going to, for the 100 patient go-no-go is five to seven sites. The assumption is that they'll enroll at least one patient a week. So, you can do the math. It’s a 100 patient randomized trial; 50 get drugs and 50 don't get drugs. By the way, David, I forgot to add, talk about the way that the dosing when Jason asked, but the – and this is actually the FDA’s recommendation, by the way. We designed it as a two-dose study on a mission and seven days later, and they pushed back and said, make it a one-dose study with a second dose if they're in the hospital. The expectation or the hope is that most of these patients actually leave the hospital by seven days. So, to treat the 360 patients that we need to treat since only half of those, or 100, you know let’s call it a 180 patients are getting treatment. Let me just say 250 vials is all we need for this clinical trial, 350 doses. So, that’s a very – it’s a beautiful thing when you’re a company doing a drug study where the drug supply is not a tremendous burden. But anyway, Arthur, back to your question, our hope is, you know, the speed of which the trial enrolls is completely dependent on how severe the disease is. We will place our sites where we think the disease is going to be active this fall and summer.

Arthur He, Analyst

Okay, thanks for that color. And just the one question on the Alzheimer’s disease program, could you remind us the beta analysis, what you could expect later this year?

RJ Tesi, CEO

So remember, just a reminder, this is a Phase I trial in patients with inflammation and Alzheimer's disease, and so they had to have biomarkers of inflammation to be enrolled because remember, our hypothesis is that neural inflammation is a cause of their disease. They get treated for three months. The primary readouts, the primary goal of the trial is to prove we get rid of neural inflammation. The hypothesis is that if we get rid of neural inflammation, then we will improve – decrease the amount of nerve cell death and synaptic dysfunction, but to get a cognitive readout is going to take more than three months. So, we are collecting all that cognition, measures, but that's not the primary endpoint. The primary endpoint is four different buckets. We have inflammatory and neurodegenerative biomarkers in blood and CSF. So, you know, cytokines, neural filament. We're using the Roche neural toolkit for these assays, so that's blood and CSF is standard. We are measured using MRI imaging to look at white matter free water, which is an area that I am quite keen on. It turns out that neural inflammation increases the amount of free water in the white matter, and you can measure that by MRI sequences. So that is a very attractive biomarker that we are getting; a breath test looking at volatile organic compounds that are expressed in the breath, which is an excellent biomarker of inflammation. Finally, we are looking at what we call behavioral biomarkers. It turns out that depression, agitation, hallucinations, sleep disorders, and apathy are common problems in Alzheimer's patients, and they are exquisitely sensitive to neural inflammation. The assumption is or the hypothesis is that these will improve. So, it's this suite of five biomarker buckets that we're looking at. Those are the endpoints that we're going to use to move into Phase II.

Arthur He, Analyst

Great. Thank you for that. And just one maybe quick housekeeping question for David. So, regarding the SG&A expense line, could that stay flat over the rest of the year?

David Moss, CFO

Yes, yes, you can, Arthur.

Operator, Operator

At this time, I would like to turn the call back over to Mr. RJ Tesi for closing comments.

RJ Tesi, CEO

So, we'd like to thank you all for joining us today. We are excited about the future. As you know, we have a full plate of programs. We are working hard in these difficult times. We have prioritized our programs in a way that we think we can bring value to the company and to investors and to make a difference at the bedside. So, with that, I thank you all, David, anything you want to add?

David Moss, CFO

No, I appreciate everybody's patience in what we're doing here, and I certainly appreciate everyone's support. As always, if you have questions, please reach out to us individually and independently, we'd be more than delighted to chat with you.

Operator, Operator

Thank you. This does conclude today's teleconference. You may disconnect your lines at this time and have a great day.